Author

Friedeborg Seitz

Observed names: F. Seitz, Seitz, Friedeborg

Institution: Clinical Research Services

Observed institution: Clinical Research Services

ORCID: 0000-0002-4460-5867

Observed ORCID: 0000-0002-4460-5867

OpenAlex ID: A5060443067

Safety and tolerability of a novel inhaled GATA3 mRNA targeting DNAzyme in patients with TH2-driven asthma

2015 · Ursula Homburg, Harald Renz, et al. · Journal of Allergy and Clinical Immunology · 52

Novel cathepsin C inhibitor, BI 1291583, intended for treatment of bronchiectasis: Phase I characterization in healthy volunteers

2024 · Philipp Badorrek, Claudia Diefenbach, et al. · Clinical and Translational Science · 14

Efficacy and safety of the ghrelin-O-acyltransferase inhibitor BI 1356225 in overweight/obesity: Data from two Phase I, randomised, placebo-controlled studies

2023 · Susanna Bianzano, Andrea Henrich, et al. · Metabolism · 14

The effect of carbamazepine, a strong CYP3A inducer, on the pharmacokinetics of zongertinib in healthy male volunteers

2024 · Xiaofan Tian, Habib Esmaeili, et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 11

Drug-drug interaction (DDI) of darolutamide with cytochrome P450 (CYP) and P-glycoprotein (P-gp) substrates: Results from clinical and in vitro studies.

2019 · Christian Zurth, Kristina Graudenz, et al. · Journal of Clinical Oncology · 9

Phase 1 trials of BI 764198, a transient receptor potential channel 6 inhibitor, in healthy volunteers and participants with kidney impairment

2025 · Armin Schultz, Atef Halabi, et al. · Expert Opinion on Investigational Drugs · 8

Phase I Characterization of the Novel Cathepsin C Inhibitor BI 1291583

2022 · P. Badorrek, C. Diefenbach, et al. · American Journal of Respiratory and Critical Care Medicine · 8

Single and Repeated Doses of EGb 761® do not Affect Pharmacokinetics or Pharmacodynamics of Rivaroxaban in Healthy Subjects

2022 · Robert Hoerr, Andrea Zimmermann, et al. · Frontiers in Pharmacology · 7

Safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 685509, a soluble guanylyl cyclase activator, in healthy volunteers: Results from two randomized controlled trials

2024 · Diane Wong, Friedeborg Seitz, et al. · Naunyn-Schmiedeberg s Archives of Pharmacology · 6

Dasiglucagon Effects on QTc in Healthy Volunteers: A Randomized, Placebo-Controlled, Dose-Escalation, Double-Blind Study

2022 · Ramin Tehranchi, Jonas Pettersson, et al. · Current Therapeutic Research · 2

First-in-Human Safety and Tolerability Study of TOP-N53, a NO-Releasing PDE5 Inhibitor, in Healthy Volunteers

2026 · Friedeborg Seitz, Hans Ulrich Gerth, et al. · medRxiv

Bioequivalence of netupitant and palonosetron (NEPA) oral suspension and hard capsules in healthy individuals: results from an open-label, randomized, two-treatment, four-period, two-sequence replicative design trial

2026 · Edis Gasanin, Riccardo Bezzo, et al. · Supportive Care in Cancer

Works count: 13

Citation count: 131

H-index: 7

I10-index: 4